This website uses cookies
Read our Privacy policy and Terms of use for more information.
GLP1
+1

Oct 6, 2026
•
10 min read
In a randomized Phase 2b trial, Lilly’s amylin-plus-tirzepatide combination showed 8.5 percentage points greater estimated weight loss than tirzepatide 15 mg. The open question is how many people can stay on it.

GLP1
+1

Oct 3, 2026
•
18 min read
A mechanism-first deep dive into the two hormones behind the next obesity drugs: what they do in the liver and the brainstem, and what the trials can and can't confirm.

GLP1
+1

Sep 30, 2026
•
17 min read
TRIUMPH-1 is in NEJM. The obvious findings first, then what's hiding underneath.

Safety
+2

Sep 26, 2026
•
8 min read
What the vision-loss headlines actually mean, and how to handle the loved ones who keep forwarding them.

GLP1
+3

Sep 23, 2026
•
11 min read
A new meta-analysis says GLP-1s reduce binge eating. It's the most rigorous synthesis we have, and the part that answers the question rests on about 130 patients.

Obesity
+3

Sep 19, 2026
•
9 min read
For two years, a very low dose worked. Then stress eating broke through it. Going to 5 mg taught me something I think patients, and obesity doctors, get wrong about these drugs.

CV
+4

Sep 15, 2026
•
10 min read
Blinded trials show most muscle symptoms blamed on statins are not caused by the statin. A real minority are. SAMSON, StatinWISE, GAUSS-3, and 123,940 pooled patients measured the difference.

CV
+4

Sep 12, 2026
•
10 min read
REACT imaged 16,808 adults aged 18 to 70. More than half had atherosclerotic plaque, and a low ten-year risk estimate did not establish that arteries were plaque-free. Whether finding plaque earlier changes outcomes is still being tested.

Lipedema
+3

Sep 9, 2026
•
14 min read
Lipedema often begins decades before it is diagnosed. In the largest U.S. patient registry, women first sought medical help at an average age of 39.6 and were not diagnosed until 48. This week Vineyard expanded its comprehensive obesity and cardiometabolic program with a dedicated lipedema effort led by one of the physicians who helped write the U.S. standard of care.

Michael Albert, MD. Board-certified obesity medicine physician. Chief Medical Officer, Vineyard.
Get the evidence in your inbox
Free, twice a week. Every number sourced to the trial. Unsubscribe anytime.
© 2026 Michael Albert MD LLC · Not medical advice. Dr. Albert is Chief Medical Officer of Vineyard.